Here are three highlights:
1. Attendees can trial the BoneScalpel and the BoneScalpel MIS.
2. The BoneScalpel MIS is intended to aid surgeons in minimally invasive procedures.
3. Misonix reported BoneScalpel global revenues increased 41 percent in the third quarter.
More articles on devices:
Opponents criticize associating research funds with FDA standards: 3 quick notes
Titan Spine makes an impact with nanotech spinal implants: 7 observations
FDA clears Orthofix’s FORZA PTC Interbody Spacer System: 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
